Innovative Therapies Days 2023
Innovative Therapies Days is the key symposium that will give a large part to exchanges between experts in their field: scientists, clinicians, and industrial partners. You will find them through an Exhibitor Village, B2B sessions, and discussion times, and discover their latest scientific progress on CAR-T cells, cell therapies, and cell-derived innovative therapies. While the Bourgogne-Franche-Comté region is the birthplace of microtechnology, it is the combination of those technologies with cell therapies that enabled the RIGHT institute to bring out flagship products like CAR-T cells! With some national partners and international partners and around 600 visitors, ITD brings together scientists, clinicians, and industrual partners for 2 days of high-level conferences about CAR-T cells, cell therapies, cell-derived innovative therapies and regulation, production, and clinical transfer of innovative therapies.
- CAR-T CELLS, CELL THERAPIES, CELL-DERIVED INNOVATIVE THERAPIES
This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.
Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.
- REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES
This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.
We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America